Financial Comparison: Clene (NASDAQ:CLNN) and Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Theravance Biopharma and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Clene	-20,063.96%	N/A	-137.04%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Theravance Biopharma and Clene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Clene	1	0	6	0	2.71

Theravance Biopharma currently has a consensus price target of $19.00, indicating a potential upside of 11.57%. Clene has a consensus price target of $34.00, indicating a potential upside of 787.73%. Given Clene’s stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Theravance Biopharma.

Valuation & Earnings

This table compares Theravance Biopharma and Clene”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	8.48	$105.89 million	$1.01	16.86
Clene	$200,000.00	248.76	-$26.17 million	($3.50)	-1.09

Theravance Biopharma has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 7.6% of Theravance Biopharma shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Theravance Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.